Balrampur Chini Q1 FY27: consolidated PAT falls 14% YoY as margins compress

Balrampur Chini Mills' consolidated Q1 FY27 (quarter ended 30 June 2026) revenue rose 6.1% YoY to ₹1,636.79 Cr (₹1,542.27 Cr a year ago), but consolidated PAT — the primary basis — fell 14.4% YoY to ₹44.15 Cr from ₹51.57 Cr, with basic EPS down to ₹2.16 from ₹2.55. Consolidated PAT includes a ₹6.49 Cr equity-accounted profit contribution from associate Auxilo Finserve Private Limited that standalone PAT of ₹38.59 Cr excludes, explaining most of the gap between the two bases this quarter. Sequentially, PAT dropped 72.3% from ₹159.57 Cr in Q4 FY26, but that comparison is not meaningful on its own: sugar is a seasonal business (the company's own filing notes say results "vary from quarter to quarter"), and Q4 (Jan-Mar) captures the bulk of the crushing/sales season, so the QoQ collapse is a structural seasonality artifact rather than a deterioration signal. No exceptional items appear in either the current or year-ago quarter, so both PAT comparisons are on a like-for-like reported basis.

Operating margin (EBITDA/revenue) compressed to 6.96% from 8.70% a year ago, and net margin to 2.67% from 3.33% (both far below Q4's seasonally elevated 17.75%/9.87%). The squeeze sits mainly below the input-cost line: employee costs rose 7.2% YoY to ₹99.68 Cr and other expenses jumped 25.7% YoY to ₹115.11 Cr, while finance costs eased slightly to ₹32.48 Cr from ₹33.67 Cr. By segment, sugar — still the core earnings driver — posted PBT of ₹38.76 Cr, down 19.4% YoY (₹48.07 Cr) even as sugar segment revenue grew to ₹1,225.27 Cr from ₹1,167.63 Cr, pointing to a realisation/cost squeeze rather than a volume problem.

The stock went into the print at ₹627.8, up 7.3% over the past month of trading.

The PLA (bioplastics) business at the centre of the diversification push flagged in the prior concall saw revenue scale to ₹17.44 Cr from just ₹0.26 Cr a year ago as the Kumbhi plant ramps toward its guided Q3 FY27 commissioning, but the segment's loss widened to ₹9.84 Cr from ₹4.01 Cr YoY — consistent with pre-commissioning ramp costs. On funding, the company completed its guided ₹450 Cr preferential allotment (9.32 Cr shares at ₹483 each) during the quarter and has utilised ₹170.74 Cr of the proceeds toward stated capex objects, with ₹279.26 Cr still parked in deposits/mutual funds; the "Preferential Issue Proceeds Utilized as Planned" disclosure this quarter confirms the funding plan is on track with prior guidance. Management gave no numeric P&L guidance in its prior commentary — the last concall focused on PLA capex cost, funding structure and promoter stake, not revenue or margin targets — so there is no formal outlook to grade growth/margins against, and no separate press release accompanied this filing. Our pre-result preview had flagged sugar realisation, Kumbhi capex economics and the FY27 margin-recovery narrative as the quarter's key watch items alongside Street's Strong Buy consensus (0-7% upside); the realisation/margin question resolved unfavourably (both OPM and NPM contracted YoY), while the preview's on-plan revenue range of ~₹850-900 Cr proved well below the ₹1,636.79 Cr actually reported — a large revenue beat that nonetheless came with a profit miss relative to the growth trajectory a Strong Buy thesis implies.